In the United States, renal cell carcinoma is currently among the 10 most frequently diagnosed cancers in both men and women. According to an estimate from the American Cancer Society (ACS), each year nearly 82,000 new cases of renal cell carcinoma will be diagnosed, while nearly 15,000 patients will die from this disease. [1]

Over the past 3 decades, the treatment of renal cell carcinoma (RCC), has seen major developments, with a growing number of treatment options. The changing landscape of therapy options include the use of immunotherapies, including interleukin-2 (Il-2; approved in 1992) and interferon-α (IFN-α), to tyrosine kinase inhibitors and mTOR inhibitors, and combinations of immune checkpoint inhibitors.

Brain metastases and renal cell carcinoma
Brain metastases, the most common type of tumors in the CNS in adults, occur in approximately 20% of malignant tumors.  And in approximately 4 – 11 percent of all cases of renal cell carcinoma, the disease tends to metastasize to the brain. [2][3]

And while the discovery of immune checkpoint inhibitors has revolutionized the treatment of renal cell carcinoma, in patients with renal cell carcinoma brain metastases,
response rates are low and survival outcomes poor. [4]

Distinct gene expression
In patients with renal cell carcinoma, brain metastases, had distinct gene expression programs and lower anti-tumor immune cell infiltration than primary tumors or metastases in other organs.

Advertisement #3

This is the conclusion of  a study presented at the annual meeting of the  American Association for Cancer Research (AACR), held April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida. [3]

The study was supported by the Kidney Cancer Association Young Investigator Award 2021, the International Kidney Cancer Coalition Cecile and Ken Youner Scholarship 2021, the Society of Immunotherapy of Cancer-Nanostring Single Cell Biology Award 2022, and Cancer Prevention and Research Institute of Texas.

Elshad Hasanov, MD, Ph.D., is a medical oncology fellow at The University of Texas MD Anderson Cancer Center.

Immune checkpoint inhibitors
“Recent studies have suggested that brain metastases might occur in over 25 percent of patients with renal cell carcinoma who are treated with immune checkpoint inhibition,” noted Elshad Hasanov, MD, Ph.D., the presenter of the study and a medical oncology fellow at The University of Texas MD Anderson Cancer Center.

“The brain is becoming a common metastatic site of disease progression in patients treated with immune checkpoint inhibition, which may be due to the fact that it is an immune-privileged organ and might, therefore, allow tumor cells to escape the activity of immunotherapy,” he explained, adding that patients whose renal cell cancers have metastasized to the brain have lower rates of treatment response and worse outcomes.

Understanding the biology of brain metastases
“To develop better treatments for these patients, we first need to understand the biology of brain metastases and identify the factors that are driving immune suppression in the brain,” he said.

To better understand the differences in the tumor microenvironment between primary kidney tumors, extracranial metastases, and brain metastases, Hasanov and colleagues compared the tumor microenvironments of brain metastases with those of primary tumors and other sites of metastasis using tissue samples from patients with renal cell carcinoma collected via collaboration with researchers at MD Anderson, Emory University, and Hacettepe University in Turkey.

Using this information, the researchers developed a detailed single-cell atlas of renal cell carcinoma brain metastases along with their matched extracranial and primary tumors.

The researchers collected samples were either frozen or formalin-fixed paraffin-embedded (FFPE) for preservation. The frozen samples included 14 brain metastases, eight matched primary kidney tumors, and five matched extracranial metastases; FFPE samples included 57 brain metastases. The researchers used a combination of single-nucleus RNA sequencing of frozen samples and spatial transcriptomics of FFPE samples to characterize gene expression and cellular interactions.

Greater infiltration
The analysis revealed that compared with primary tumors or extra-cranial metastases, brain metastases had greater infiltration of neuronal and glial cells into the tumor microenvironment.

Hasanov explained that interactions between these brain cells and tumor cells were previously shown to enhance cancer growth and metastasis. The researchers also observed that neuronal and glial cell interaction with immune cells potentially suppressed anti-tumor immune activity through known immunosuppressive ligand-receptor interactions.

The tumor microenvironment of brain metastases had fewer proliferating T-cells, memory B cells, dendritic cells, and monocytes than primary tumors and extracranial metastases. Furthermore, T-cells in brain metastases expressed higher levels of immune checkpoint proteins than T-cells in other sites, and macrophages in the brain were more likely to express an immune-suppressing M2 gene signature.

The researchers also noted that tumor cells in the brain had greater expression of serum amyloid A1, which promotes immune-suppressive effects in macrophages; higher activity of the VEGFR and FGFR4 growth-promoting proteins; and greater expression of genes that allowed them to adapt to the brain environment, including MYC target genes and genes involved in mTORC1 signaling, epithelial-mesenchymal transition, fatty acid metabolism, oxidative phosphorylation, and the response to reactive oxygen species.

“Our study highlights the power of single-nucleus RNA sequencing and spatial transcriptomics to uncover facets of disease biology,” Hasanov said.

These results provide a foundation for a deeper understanding of the biology of renal cell carcinoma brain metastasis, and serve as a resource for the scientific community to further explore therapeutically targetable tumor and immune-related mechanisms.

“The immune-suppressive features identified in our analysis have the potential to serve as biomarkers or therapeutic targets for patients with renal cell carcinoma that has metastasized to the brain. We hope that the findings of this study will contribute to the design of better therapies for these patients,” he added.

Ongoing studies
Based on the findings from this study, Hasanov and colleagues plan to initiate a multicenter clinical trial to evaluate lenvatinib (Lenvima®; Eisai), a multi-target tyrosine kinase inhibitor of VEGFR, FGFR4, and other receptors, in combination with pembrolizumab (Keytruda®; Merck & Co) for patients with renal cell carcinoma who have brain metastases.

“While this regimen is currently approved for the first-line treatment of patients with metastatic renal cell carcinoma, prior trials testing this combination did not include patients with active brain metastases,” Hasanov said.

In future work, Hasanov intends to pursue preclinical experiments and clinical trials to determine whether various combinations of tumor targeting agents and inhibitors of
immune checkpoints in the tumor microenvironment of brain metastases could help overcome immune suppression.

Study limitations
Limitations of the study include its retrospective design and the small sample size. Additionally, all brain metastases were obtained from patients who had undergone dexamethasone treatment prior to craniotomy, which might have impacted the results. However, Hasanov noted that this treatment is common among patients with brain metastases, so the results likely reflect the microenvironments of most patients.

Highlight of prescribing information
Lenvatinib (Lenvima®; Eisai) [Prescribing information]
Pembrolizumab (Keytruda®; Merck & Co) [Prescribing Information]

Reference
[1] Key statistics about kidney cancer; how common is kidney cancer. American Cancer Society (ACS). Online. Last accessed on April 16, 2023.
[2] Achrol AS, Rennert RC, Anders C, Soffietti R, Ahluwalia MS, Nayak L, Peters S, Arvold ND, Harsh GR, Steeg PS, Chang SD. Brain metastases. Nat Rev Dis Primers. 2019 Jan 17;5(1):5. doi: 10.1038/s41572-018-0055-y. PMID: 30655533.
[3] Kolsi F, Mechergui H, Kammoun B, Mellouli M, Khrifech M, Zaher Boudawara M. Delayed brain metastasis from renal cell carcinoma. Urol Case Rep. 2018 Nov 5;22:54-56. doi: 10.1016/j.eucr.2018.10.020. PMID: 30425927; PMCID: PMC6230915.
[4] Hasanov E, Nguyen T, Lam A, Lin J, Reville PK,  Hasanov M, Casasent AK, Shih D,  Hanalioglu S, Bilen MA, Alhalabi O, Babaoglu B, Baylarov B, Osunkoya AO,
Norberg LM, Gumin J, Tran TM, Li J, Hoang AG,  Chancoco HD, Parker Kerrigan BC, Thompson EJ, Kim BYS, Suki D, Mut M, Soylemezoglu F, Genovese G, Akdemir KC, Tawbi HA, Tannir NM, McAllister F, Davies MA, Sharma P, Huse J, Lang F, Navin N, Jonasch E. Single-cell and spatial transcriptomic mapping of human renal cell carcinoma brain
metastases uncovers actionable immune-resistance targets In: Proceedings of the 114th Annual Meeting of the American Association for Cancer Research; 2023 April 14-19; Orlando, FL. Philadelphia (PA): AACR; 2023. Abstract nr 5788.

 

Featured image: Human kidney by Robina Weermeijer on Unsplash. Used with permission.

Advertisement #5